Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 16/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 11/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 5/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31224124 | 0.79 | BACE1 (0.36) | BACE1 | |
| SCHEMBL31224273 | 0.77 | BACE1 (0.35) | BACE1 | |
| SCHEMBL31224280 | 0.77 | BACE1 (0.35) | BACE1 | |
| SCHEMBL23726417 | 0.76 | IRAK4 (0.35) | IRAK4CD274PDCD1PDCD1LG2 | |
| SCHEMBL31224068 | 0.75 | BACE1 (0.36) | BACE1 | |
| SCHEMBL31224468 | 0.74 | ATM (0.33) | — | |
| SCHEMBL31223944 | 0.74 | BACE1 (0.31) | BACE1 | |
| SCHEMBL23725374 | 0.74 | CD274 (0.40) | IRAK4CD274PDCD1PDCD1LG2 | |
| SCHEMBL23725248 | 0.73 | SSTR4 (0.36) | IRAK4CD274PDCD1PDCD1LG2 | |
| SCHEMBL31224446 | 0.72 | CD274 (0.43) | CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024259171-A9 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | IRAK4 2045/4885CD274 3550/4885PDCD1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.